NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
Clinical Trials
157 trialsNCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT04799054 2026-01-20
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT06523803 2025-10-21
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Zymeworks BC Inc.
Phase 1 Terminated
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05490043 2025-08-29
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Corporation
Phase 1 Terminated
NCT06877533 2025-08-12
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Terminated
NCT04717375 2025-08-07
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT04875871 2025-05-11
PARTICLE-PATHY
EBG MedAustron GmbH
Phase NA Terminated
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05904236 2025-04-08
ICVB-1042
IconOVir Bio
Phase 1 Terminated
NCT05429762 2025-04-06
TusaRav-QT
Sanofi
Phase 1 Terminated
NCT05126433 2025-02-28
JAZZ EMERGE201
Jazz Pharmaceuticals
Phase 2 Terminated
NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT02187848 2025-02-10
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05781360 2024-12-20
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04528836 2024-12-12
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Navire Pharma Inc., a BridgeBio company
Phase 1 Terminated
NCT06290388 2024-12-04
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
23andMe, Inc.
Phase 1/2 Terminated
NCT03915717 2024-11-26
Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Sonavex, Inc.
Terminated
NCT05198349 2024-11-25
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono
Phase 1 Terminated
NCT05525455 2024-11-21
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Teon Therapeutics, Inc.
Phase 1/2 Terminated
NCT03783403 2024-09-19
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
Phase 1 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT03416335 2024-05-30
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT05631327 2024-05-28
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Terminated
NCT04618393 2024-05-21
A Study of EMB-02 in Participants With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Terminated
NCT04250597 2024-05-06
Study of GNX102 in Patients With Advanced Solid Tumors
GlycoNex, Inc.
Phase 1 Terminated
NCT04349280 2024-04-18
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT03604445 2024-03-04
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Terminated
NCT05133128 2024-02-22
IMMUNOPBMC
Servier
Phase NA Terminated
NCT01311713 2024-01-30
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT03416816 2023-11-14
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1 Terminated
NCT03637764 2023-07-10
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT00886782 2023-04-28
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02452268 2023-03-03
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis
Phase 1 Terminated
NCT03251924 2023-02-28
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04857008 2022-10-20
BNT001 Digital Therapeutic Feasibility Pilot Study
Blue Note Therapeutics
Phase NA Terminated